Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 8/20 | 0.47 |
| ▸ | MC4R | P32245 | 8/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1310191 | 0.88 | MC1R (0.49) | MC1RMC4RLPAR1AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1310200 | 0.88 | MC1R (0.49) | MC1RMC4R | |
| SCHEMBL20450443 | 0.86 | MC1R (0.51) | MC1RMC4RAKT1AKT2AKT3 | |
| SCHEMBL1311385 | 0.86 | MC1R (0.49) | MC1RMC4RLPAR1AKT1AKT2 | |
| Trifluoroacetic Acid SCHEMBL1310217 | 0.85 | MC1R (0.57) | MC1RMC4RAKT1AKT2AKT3 | |
| Trifluoroacetic Acid SCHEMBL1312510 | 0.83 | MC1R (0.55) | MC1RMC4RAKT1AKT2AKT3 | |
| Trifluoroacetic Acid SCHEMBL1310190 | 0.82 | MC1R (0.48) | MC1RMC4R | |
| Hydrochloric Acid SCHEMBL1310496 | 0.82 | MC1R (0.60) | MC1RMC4RAKT1AKT2AKT3 | |
| Hydrochloric Acid SCHEMBL1310494 | 0.82 | MC1R (0.60) | MC1RMC4RAKT1AKT2AKT3 | |
| SCHEMBL2154187 | 0.80 | MC1R (0.52) | MC1RMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630949-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-04-25 | — | — | US | disclosed |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-12 | — | — | US | disclosed |
| US-8871187-B2 | Oxoazetidine derivatives, process for the preparation thereof and use thereon in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-10-28 | — | — | US | disclosed |
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110274638-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREON IN HUMAN MEDICINE AND IN COSMETICS | CYP2D6, CYP51A1, CYP2C19 | MC1R 326/4885MC4R 1479/4885SIGMAR1 2380/4885 |
| US-20150045559-A1 | OXOAZETIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | CYP51A1, TYR, CYP2C19 | MC1R 195/4885MC4R 873/4885SIGMAR1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.